Free Trial

Aberdeen Group plc Buys 603,440 Shares of Travere Therapeutics, Inc. $TVTX

Travere Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group increased its Travere Therapeutics stake by 483.3%, buying 603,440 shares in the third quarter to hold 728,295 shares, valued at about $42.9 million.
  • Travere reported quarterly revenue of $224.6 million, up 36.2% year over year and above estimates, but its loss of $0.55 per share was substantially wider than analysts expected.
  • Company insiders sold about 1.29 million shares worth $79.5 million over the past 90 days. Analysts’ overall rating was “Moderate Buy,” with a consensus price target of $72.55.
  • Five stocks we like better than Travere Therapeutics.

Aberdeen Group plc lifted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 483.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 728,295 shares of the company's stock after purchasing an additional 603,440 shares during the period. Aberdeen Group plc owned about 0.76% of Travere Therapeutics worth $42,882,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new stake in shares of Travere Therapeutics in the second quarter valued at $643,299,000. Bank of America Corp DE acquired a new position in Travere Therapeutics during the second quarter worth $259,527,000. Assenagon Asset Management S.A. lifted its position in shares of Travere Therapeutics by 168.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company's stock valued at $67,442,000 after acquiring an additional 718,109 shares during the period. Wellington Management Group LLP increased its position in shares of Travere Therapeutics by 50.0% in the second quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company's stock valued at $87,094,000 after buying an additional 510,808 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Travere Therapeutics in the second quarter valued at approximately $26,723,000.

Insider Buying and Selling at Travere Therapeutics

In related news, insider Elizabeth Reed sold 37,500 shares of the firm's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total transaction of $2,337,750.00. Following the completion of the sale, the insider directly owned 105,389 shares of the company's stock, valued at $6,569,950.26. This trade represents a 26.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Dube sold 243,735 shares of Travere Therapeutics stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $53.82, for a total value of $13,117,817.70. Following the completion of the transaction, the chief executive officer owned 432,886 shares of the company's stock, valued at approximately $23,297,924.52. The trade was a 36.02% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,294,029 shares of company stock worth $79,454,261 over the last 90 days. Company insiders own 4.44% of the company's stock.

Travere Therapeutics Price Performance

TVTX opened at $50.65 on Monday. Travere Therapeutics, Inc. has a fifty-two week low of $22.59 and a fifty-two week high of $68.73. The company has a debt-to-equity ratio of 26.72, a current ratio of 3.00 and a quick ratio of 2.95. The firm's fifty day moving average price is $55.93 and its two-hundred day moving average price is $47.55. The company has a market capitalization of $4.86 billion, a P/E ratio of -39.26 and a beta of 1.11.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.49). Travere Therapeutics had a negative net margin of 18.66% and a negative return on equity of 185.69%. The company had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The firm's revenue for the quarter was up 36.2% compared to the same quarter last year. On average, analysts anticipate that Travere Therapeutics, Inc. will post -0.90 EPS for the current year.

Wall Street Analyst Weigh In

TVTX has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Travere Therapeutics in a research note on Friday, September 18th. Zacks Research downgraded shares of Travere Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 20th. JPMorgan Chase & Co. decreased their target price on Travere Therapeutics from $90.00 to $86.00 and set an "overweight" rating for the company in a research report on Friday, November 6th. Wedbush restated an "outperform" rating and issued a $76.00 target price on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Finally, Piper Sandler restated an "overweight" rating on shares of Travere Therapeutics in a research report on Monday, August 17th. Eleven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $72.55.

View Our Latest Stock Report on Travere Therapeutics

Travere Therapeutics Company Profile

(Free Report)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.

See Also

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Travere Therapeutics Right Now?

Before you consider Travere Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.

While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines